SELE and malignant colon neoplasm: The derivative benzyl-αGalNAc (15; Scheme 1) was shown to decrease the level of sialylation and sulfation of mucins secreted by the human colon carcinoma cell line HT-29 MTX (168), and also decreased the binding of treated HM7 colon cancer cells to E-selectin [ELAM-1, recognizes sialyl Lea and sialyl Lex (169)], which would be a desirable effect in modifying the immunological and biological properties of colon cancer cells.